Germany’s Merck forecasts little or no improvement in earnings this year after a slight drop in fourth-quarter net profit, with stiff competition for its blockbuster multiple-sclerosis treatment and higher research spending likely to offset the impact of recent acquisitions.
from WSJ.com: US Business http://ift.tt/1EcgL0L
via IFTTT
from WSJ.com: US Business http://ift.tt/1EcgL0L
via IFTTT
No comments:
Post a Comment